These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 414829)

  • 21. [Combined treatment of lung carcinoma. Report on a prospective randomized study with radiotherapy and ICRF 159 (1,2-(3,5-dioxopiperazines-lyl)propane) (author's transl)].
    Hassenstein E; Rhomberg W
    Med Klin; 1977 Feb; 72(5):171-5. PubMed ID: 403395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
    Vogl SE; Lanham R; Kaplan BH
    Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Razoxane (ICRF 159) in the treatment of psoriasis.
    Atherton DJ; Wells RS; Laurent MR; Williams YF
    Br J Dermatol; 1980 Mar; 102(3):307-17. PubMed ID: 7370178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Razoxane in treatment of acute myeloid leukaemia.
    Bhavnani M; Dhir K; Delamore IW
    Br Med J; 1978 Sep; 2(6140):801. PubMed ID: 279388
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
    Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
    Bonomi P; Yordan E; Blessing JA
    Am J Clin Oncol; 1988 Feb; 11(1):1-2. PubMed ID: 3277372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
    DeSimone PA; Greco FA; Omura GA; Bartolucci A
    Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 30. Preliminary report on AT1727 as a potential radiosensitizer.
    Zhang ZY; Liu TF; Zhang XF
    Int J Radiat Oncol Biol Phys; 1984 Dec; 10(12):2305-7. PubMed ID: 6392223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five-year follow-up.
    Gilbert JM; Hellmann K; Evans M; Cassell PG; Taylor RH; Stoodley B; Ellis H; Wastell C
    Br J Surg; 1986 Jun; 73(6):446-50. PubMed ID: 3521784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of combined modality therapy for localized high-grade soft tissue sarcomas in adults.
    Blum RH; Greenberger JS; Wilson RE; Corson JM
    Int J Radiat Oncol Biol Phys; 1979 Aug; 5(8):1281-5. PubMed ID: 118950
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
    Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
    Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
    Flannery EP; Corder MP; Sheehan WW; Pajak TF; Bateman JR
    Cancer Treat Rep; 1978 Mar; 62(3):465-7. PubMed ID: 348318
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of experimental colorectal cancer by razoxane (ICRF-159).
    Gilbert JM; Thompson EM; Slavin G; Kark AE
    Br J Surg; 1984 Aug; 71(8):600-3. PubMed ID: 6743979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study.
    Belloni C; Mangioni C; Bortolozzi G; Carinelli S; D'Incalci M; Maggioni A; Morasca L
    Oncology; 1983; 40(3):181-5. PubMed ID: 6341912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ICRF-159 versus polychemotherapy in non-small cell lung cancer.
    Eagan RT; Carr DT; Coles DT; Rubin J; Frytak S
    Cancer Treat Rep; 1976 Jul; 60(7):947-8. PubMed ID: 64297
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

  • 39. A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma.
    Bellet RE; Catalano RB; Danna VG; Berd DA; Berkelhammer J; Mastrangelo MJ
    J Clin Pharmacol; 1976; 16(8-9):433-8. PubMed ID: 787016
    [No Abstract]   [Full Text] [Related]  

  • 40. Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate.
    Mom A; Aresca S; Fuente G; Pecorini V; Pellerano G; Perez V
    Acta Derm Venereol; 1982; 62(4):357-8. PubMed ID: 6183878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.